

03/20/00
JC780 U.S. PTO

3-21-50

A
PATENT

Attorney Docket No.: 3951.224-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL473440171US
Date of Deposit March 20, 2000

JC530 U.S. PTO
09/528644
03/20/00


Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)
of

Applicant(s): Thim et al.

Title: Human Spasmolytic Polypeptide in Glycosylated Form

39 pages of specification 9 sheets of drawings

3 sheets of Declaration and Power of Attorney

The filing fee is calculated as follows:

Basic Fee: \$690.00

Total Claims: $12 - 20 = 0 \times 18 =$ \$0

Independent Claims: $2 - 3 = 0 \times 78 =$ \$0

Total Fee: \$690.00

Priority of Danish application no. 0068/93 filed on January 21, 1993 is claimed
under 35 U.S.C. 119.

The benefit of application nos. 08/491,976 and 09/027,893 filed on August 2, 1995
and February 23, 1998 in the U.S. and PCT/DK94/00037 filed January 20, 1994 via the
PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 20, 2000

Carol E. Rozek
Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: Human Spasmolytic Polypeptide in Glycosylated Form
Applicants: Thim et al.

Sir:

Express Mail Label No. EL473440171US

Date of Deposit : March 20, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Request Transfer of Computer Readable Sequence Listing
6. Information Disclosure Statement
7. PTO 1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly
(Name of person mailing paper(s) or fee)

Miriam Kelly
(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123